Jeremy Robert Greenwood

This inventor holds 74 USPTO granted patents and 33 published patent applications, plus 6 CIPO patents and 25 EPO patents, primarily in Drug Discovery (CPC class C07D). Top assignees: Nimbus Lakshmi, Inc., Gilead Apollo, LLC, Nimbus Iris, Inc.. Active years: 2014-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jeremy Robert Greenwood. Retrieved from https://idiyas.com/inventor/jeremy-robert-greenwood

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 74 (Patent Applications = 33)

% Patents Active = 77.0

CIPO Patents = 6 (Patent Applications = 15)

EPO Patents = 25 (Patent Applications = 47)

Average Co-Inventor Count = 5.5

ph-index = 10

Forward Citations = 388(Granted Patents)

Forward Citations (Not Self Cited) = 192(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

Nimbus Lakshimi, Inc.

patents

6. 5 out of 5

Ajax Therapeutics, Inc.

patents

7. 4 out of 7

Bikam Pharmaceuticals Inc.

Takeda Pharmaceutical Company Limited

Years Active: 2014-2026

Loading Chart...

Areas of Expertise:

HPK1 Antagonists

JAK2 Inhibitors

TYK2 Inhibitors

Drug Discovery

Pyrrolo Compounds

Benzimidazoles

Pyrazole Compounds

ACC Inhibitors

Ester Inhibitors

Pesticidal Compositions

Isoindolin Compounds

Triazole Compounds

74 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12774274 - Heterocyclic compounds and methods of use (2026-10-27),

2. 12715876 - Cyclic compounds and methods of using same (2026-08-25),

3. 12686688 - Heterocyclic pericondensed CDC7 kinase inhibitors for the treatment of cancer (2026-07-21),

4. 12466841 - Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists (2025-11-11),

5. 12325697 - CBL-B modulators and uses thereof (2025-06-10),

6. 12275717 - 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors (2025-04-14),

7. 12221453 - Substituted pyrazolo[5',1′:2,3]pyrimido[5,4-b][1,4]oxazines as TYK2 inhibitors (2025-02-11),

8. 12215105 - HPK1 antagonists and uses thereof (2025-02-04),

9. 12162881 - Forms and compositions of inhibitors of JAK2 (2024-12-10),

10. 12071442 - Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists (2024-08-27),

11. 12043632 - 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors (2024-07-23),

12. 11970494 - 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors (2024-04-30),

13. 11834449 - TYK2 inhibitors and uses thereof (2023-12-05),

14. 11710543 - Methods for predicting an active set of compounds having alternative cores, and drug discovery methods involving the same (2023-07-25),

15. 11691963 - 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors (2023-07-04),

Title: The Innovation Journey of Jeremy Robert Greenwood: A Brooklyn-Based Patent Powerhouse

Introduction:

Jeremy Robert Greenwood, a prolific inventor based in Brooklyn, NY, has made a significant impact in the field of pharmaceuticals and drug development. With an impressive portfolio of 63 patents to his name, Greenwood continues to push the boundaries of innovation in JAK2 and TYK2 inhibitors.

Latest Patents:

Greenwood's latest patents showcase his expertise in developing cutting-edge compounds for inhibiting JAK2 and TYK2. The "6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors" patent highlights his contribution to the treatment of JAK2-mediated disorders. Similarly, the "TYK2 inhibitors and uses thereof" patent underscores his commitment to advancing treatments for TYK2-related conditions.

Career Highlights:

Throughout his career, Greenwood has lent his talents to renowned companies such as Nimbus Lakshmi, Inc. and Gilead Apollo, LLC. His innovative spirit and dedication to scientific excellence have undoubtedly played a pivotal role in the success of these organizations. Greenwood's relentless pursuit of groundbreaking solutions has solidified his reputation as a trailblazer in the pharmaceutical industry.

Collaborations:

Greenwood has had the privilege of collaborating with industry stalwarts such as Craig E Masse and Geraldine C Harriman. These partnerships have not only enriched his own work but have also paved the way for collaborative breakthroughs in drug development and molecular science.

Conclusion:

In conclusion, Jeremy Robert Greenwood stands as a shining example of innovation and ingenuity in the world of pharmaceutical inventions. His unwavering commitment to scientific advancement, coupled with his impressive patent portfolio, cements his legacy as a visionary inventor shaping the future of medical treatments.

Profile summary based on public USPTO records.